Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QURE
stocks logo

QURE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
5.94M
+13.89%
-0.918
-38.77%
6.82M
+335.74%
-0.895
+9.24%
7.87M
+50.45%
-0.911
+31.83%
Estimates Revision
The market is revising Downward the revenue expectations for uniQure N.V. (QURE) for FY2025, with the revenue forecasts being adjusted by -45.21% over the past three months. During the same period, the stock price has changed by 26.69%.
Revenue Estimates for FY2025
Revise Downward
down Image
-45.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+18.88%
In Past 3 Month
Stock Price
Go Up
up Image
+26.69%
In Past 3 Month
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 62.60 USD with a low forecast of 38.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 62.60 USD with a low forecast of 38.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 22.740
sliders
Low
38.00
Averages
62.60
High
95.00
Current: 22.740
sliders
Low
38.00
Averages
62.60
High
95.00
Leerink
Outperform
to
NULL
downgrade
$68 -> $60
2025-11-10
Reason
Leerink
Price Target
$68 -> $60
2025-11-10
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on uniQure to $60 from $68 and keeps an Outperform rating on the shares following quarterly results and earnings call, which was "unsurprisingly" focused on the regulatory path for AMT-130 in Huntington's disease. Leerink acknowledges the "surprise" last week when uniQure sounded the alarm and disclosed that the FDA no longer agreed that the data from the Phase 1/2 studies and prespecified analyses vs. an external control may be adequate to provide primary evidence in support of a BLA submission. On the call today, uniQure emphasized that this FDA reversal does not change their data for AMT-130 in HD that support real and serious disease modification. While this news has made timing of a BLA submission uncertain, the company plans to urgently engage with the FDA to discuss next steps, beginning with the formal meeting minutes.
William Blair
Myles Minter
Outperform -> Market Perform
downgrade
2025-11-05
Reason
William Blair
Myles Minter
Price Target
2025-11-05
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Myles Minter downgraded Biohaven (BHVN) to Market Perform from Outperform. The announcement of a CRL for troriluzole in spinocerebellar ataxia halts not only a near-term source of revenue but also the ability of the company to access $150M in capital through its note purchase agreement with Oberland Capital, the analyst tells investors. Even with a 60% reduction in annual R&D spending, the firm believes Biohaven will need additional capital to continue to fund its pipeline or seek strategic alternatives for its deprioritized pipeline assets, notes the analyst, who is moving to the sidelines to await regulatory clarity given that the FDA has now been restrictive to both uniQure's (QURE) and Biohaven's comparisons to natural history as a regulatory path forward in rare neurological disorders.
William Blair
Sami Corwin
Outperform -> Market Perform
downgrade
2025-11-04
Reason
William Blair
Sami Corwin
Price Target
2025-11-04
downgrade
Outperform -> Market Perform
Reason
William Blair analyst Sami Corwin downgraded uniQure to Market Perform from Outperform.
William Blair
William Blair
Outperform -> Market Perform
downgrade
2025-11-04
Reason
William Blair
William Blair
Price Target
2025-11-04
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded uniQure to Market Perform from Outperform without a price target. The company announced that following a recent meeting, it believes the FDA no longer agrees that the data from the Phase I/II trial of AMT-130 in comparison to external controls support an application submission because the statistical analysis plan was not proposed prior to the start of the trial, the analyst tells investors in a research note. The firm views the development as a "significant divergence" from the guidance provided by the agency in November 2024. Blair believes the path forward for AMT-130 is now uncertain.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$110 -> $70
2025-11-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$110 -> $70
2025-11-04
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on uniQure to $70 from $110 and keeps a Buy rating on the shares. The firm says the FDA's shift on AMT-130 is a significant but surmountable. It is confident that a viable regulatory path should emerge. The selloff yesterday in uniQure shares overstates the fundamental impact of the news, the analyst tells investors in a research note.
Goldman Sachs
Neutral
downgrade
$56 -> $38
2025-11-04
Reason
Goldman Sachs
Price Target
$56 -> $38
2025-11-04
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on uniQure to $38 from $56 and keeps a Neutral rating on the shares. uniQure shares fell about 50% after the FDA withdrew support for a BLA submission of AMT-130 in Huntington's disease, citing insufficient evidence from the Phase 1/2 trial to establish efficacy, the analyst tells investors in a research note. The agency highlighted limitations in the study's design and reliance on post-hoc comparisons to external controls. The regulatory path forward remains uncertain as uniQure seeks further FDA engagement under breakthrough therapy designation and awaits meeting minutes for clarification, Goldman says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Uniqure NV (QURE.O) is -6.22, compared to its 5-year average forward P/E of -5.97. For a more detailed relative valuation and DCF analysis to assess Uniqure NV 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.97
Current PE
-6.22
Overvalued PE
9.20
Undervalued PE
-21.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.97
Undervalued EV/EBITDA
-11.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
16.51
Current PS
0.00
Overvalued PS
37.38
Undervalued PS
-4.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

QURE News & Events

Events Timeline

(ET)
2025-12-04
16:20:00
Major Averages Close Little Changed as Jobless Claims Fall to 191,000
select
2025-12-04
12:00:00
Major U.S. Indices Little Changed as Investors Anticipate Fed Rate Cut
select
2025-12-04
07:10:00
uniQure Receives FDA Meeting Minutes, AMT-130 BLA Application Faces Challenges
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:30 AMBenzinga
PinnedReasons Behind the Decline in uniQure Stock Following FDA Meeting Update

  • Stock Performance: uniQure N.V. (NASDAQ: QURE) shares are down 11.24% to $22.60 as they retreat from recent levels.

  • FDA Meeting Feedback: The company received final meeting minutes from the FDA indicating that data from Phase 1/2 studies of AMT-130 for Huntington’s disease are unlikely to support a Biologics License Application (BLA) submission.

  • Future Plans: uniQure is evaluating the FDA's feedback and plans to urgently request a follow-up meeting in the first quarter of 2026.

  • Market Analyst Insights: Analysts from William Blair express surprise at the FDA's change in guidance and note that uniQure's stock will remain under pressure until a clear path to regulatory submission is established.

[object Object]
Preview
9.0
12-04NASDAQ.COM
PinnedWhat’s Causing UniQure Stock to Decline in Pre-market Trading?

  • FDA Meeting Outcome: uniQure N.V. received final meeting minutes from the FDA regarding their pre-Biologics License Application meeting for AMT-130, indicating that current Phase I/II data may not support a BLA submission.

  • Follow-Up Plans: The company is evaluating the FDA's feedback and intends to urgently request a follow-up meeting in the first quarter of 2026.

  • Market Reaction: Following the news, shares of uniQure fell by 18% in pre-market trading.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect those of Nasdaq, Inc.

[object Object]
Preview
9.0
12-04SeekingAlpha
PinneduniQure Shares Decline Following FDA Comments on AMT-130 Pre-Application

  • FDA Meeting Notes Impact: uniQure N.V. shares fell approximately 20% after receiving final meeting notes from the FDA, indicating that data from phase I/II trials of AMT-130 may not suffice for a Biologics License Application (BLA) submission.

  • Company's Response: In light of the FDA's feedback, uniQure is reviewing the information and plans to request a follow-up meeting with the agency, targeting the first quarter of 2026 for this discussion.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Uniqure NV (QURE) stock price today?

The current price of QURE is 22.74 USD — it has decreased -10.75 % in the last trading day.

arrow icon

What is Uniqure NV (QURE)'s business?

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

arrow icon

What is the price predicton of QURE Stock?

Wall Street analysts forecast QURE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QURE is 62.60 USD with a low forecast of 38.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Uniqure NV (QURE)'s revenue for the last quarter?

Uniqure NV revenue for the last quarter amounts to 3.70M USD, increased 61.83 % YoY.

arrow icon

What is Uniqure NV (QURE)'s earnings per share (EPS) for the last quarter?

Uniqure NV. EPS for the last quarter amounts to -1.38 USD, increased 51.65 % YoY.

arrow icon

What changes have occurred in the market's expectations for Uniqure NV (QURE)'s fundamentals?

The market is revising Downward the revenue expectations for uniQure N.V. (QURE) for FY2025, with the revenue forecasts being adjusted by -45.21% over the past three months. During the same period, the stock price has changed by 26.69%.
arrow icon

How many employees does Uniqure NV (QURE). have?

Uniqure NV (QURE) has 209 emplpoyees as of December 05 2025.

arrow icon

What is Uniqure NV (QURE) market cap?

Today QURE has the market capitalization of 1.42B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free